Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAP-001 in Gout Patients With Hyperuricemia
NCT03857165Phase 1Completed
- Sponsor
- Shanton Pharma
- Start
- Sep 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sap-001 in gout and hyperuricemia (4 arms), sponsored by Shanton Pharma. Primary endpoints: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 5 days, Maximum observed plasma concentration at 5 days and 8 more. Started Sep 2018; status: completed.
02
Drugs
sap-001
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT03857165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03857165.